350 related articles for article (PubMed ID: 12663723)
21. A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell BA; Brockway GN; Shuster JJ; Erdmann G; Sterikoff S; Bostrom B; Camitta BM;
Pediatr Blood Cancer; 2004 Aug; 43(2):105-9. PubMed ID: 15236274
[TBL] [Abstract][Full Text] [Related]
22. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia.
Lennard L; Lilleyman JS
J Clin Oncol; 1989 Dec; 7(12):1816-23. PubMed ID: 2585022
[TBL] [Abstract][Full Text] [Related]
23. Role of TPMT and ITPA variants in mercaptopurine disposition.
Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Balis FM; Holcenberg JS; Poplack DG; Ge J; Sather HN; Murphy RF; Ames MM; Waskerwitz MJ; Tubergen DG; Zimm S; Gilchrist GS; Bleyer WA
Blood; 1998 Nov; 92(10):3569-77. PubMed ID: 9808549
[TBL] [Abstract][Full Text] [Related]
25. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb N; Harms DO; Janka-Schaub G
Cancer Chemother Pharmacol; 1998; 42(4):266-72. PubMed ID: 9744770
[TBL] [Abstract][Full Text] [Related]
27. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
28. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
[TBL] [Abstract][Full Text] [Related]
29. Maintenance therapy for acute lymphoblastic leukemia: basic science and clinical translations.
Toksvang LN; Lee SHR; Yang JJ; Schmiegelow K
Leukemia; 2022 Jul; 36(7):1749-1758. PubMed ID: 35654820
[TBL] [Abstract][Full Text] [Related]
30. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial.
Mahoney DH; Shuster J; Nitschke R; Lauer SJ; Winick N; Steuber CP; Camitta B
J Clin Oncol; 1998 Jan; 16(1):246-54. PubMed ID: 9440749
[TBL] [Abstract][Full Text] [Related]
31. The circadian schedule for childhood acute lymphoblastic leukemia maintenance therapy does not influence event-free survival in the NOPHO ALL92 protocol.
Clemmensen KK; Christensen RH; Shabaneh DN; Harila-Saari A; Heyman M; Jonsson OG; Wesenberg F; Rosthøj S; Schmiegelow K;
Pediatr Blood Cancer; 2014 Apr; 61(4):653-8. PubMed ID: 24265159
[TBL] [Abstract][Full Text] [Related]
32. Metabolites of mercaptopurine in red blood cells: a relationship between 6-thioguanine nucleotides and 6-methylmercaptopurine metabolite concentrations in children with lymphoblastic leukemia.
Chrzanowska M; Kolecki P; Duczmal-Cichocka B; Fiet J
Eur J Pharm Sci; 1999 Aug; 8(4):329-34. PubMed ID: 10425383
[TBL] [Abstract][Full Text] [Related]
33. Benefits of the intermittent use of 6-mercaptopurine and methotrexate in maintenance treatment for low-risk acute lymphoblastic leukemia in children: randomized trial from the Brazilian Childhood Cooperative Group--protocol ALL-99.
Brandalise SR; Pinheiro VR; Aguiar SS; Matsuda EI; Otubo R; Yunes JA; Pereira WV; Carvalho EG; Cristofani LM; Souza MS; Lee ML; Dobbin JA; Pombo-de-Oliveira MS; Lopes LF; Melnikoff KN; Brunetto AL; Tone LG; Scrideli CA; Morais VL; Viana MB
J Clin Oncol; 2010 Apr; 28(11):1911-8. PubMed ID: 20212252
[TBL] [Abstract][Full Text] [Related]
34. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia.
Winick N; Shuster JJ; Bowman WP; Borowitz M; Farrow A; Jacaruso D; Buchanan GR; Kamen BA
J Clin Oncol; 1996 Oct; 14(10):2803-11. PubMed ID: 8874342
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate binds to recombinant thiopurine S-methyltransferase and inhibits enzyme activity after high-dose infusions in childhood leukaemia.
Wennerstrand P; Mårtensson LG; Söderhäll S; Zimdahl A; Appell ML
Eur J Clin Pharmacol; 2013 Sep; 69(9):1641-9. PubMed ID: 23660772
[TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: influence on cure rates and risk of second cancer.
Levinsen M; Rotevatn EØ; Rosthøj S; Nersting J; Abrahamsson J; Appell ML; Bergan S; Bechensteen AG; Harila-Saari A; Heyman M; Jonsson OG; Maxild JB; Niemi M; Söderhäll S; Schmiegelow K;
Pediatr Blood Cancer; 2014 May; 61(5):797-802. PubMed ID: 24395436
[TBL] [Abstract][Full Text] [Related]
37. Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study.
Bhatia S; Landier W; Hageman L; Chen Y; Kim H; Sun CL; Kornegay N; Evans WE; Angiolillo AL; Bostrom B; Casillas J; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Wong FL; Relling MV
JAMA Oncol; 2015 Jun; 1(3):287-95. PubMed ID: 26181173
[TBL] [Abstract][Full Text] [Related]
38. [Significance of TPMT activity and TGNs level detection for individualizing 6-mercaptopurine chemotherapy].
Gu LJ; Ye QD; Liang AB; Zhao JC; Xue HL; Tang YN; Chen J; Ye YC
Zhonghua Xue Ye Xue Za Zhi; 2003 Jan; 24(1):18-21. PubMed ID: 12679004
[TBL] [Abstract][Full Text] [Related]
39. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1.
Landier W; Hageman L; Chen Y; Kornegay N; Evans WE; Bostrom BC; Casillas J; Dickens DS; Angiolillo AL; Lew G; Maloney KW; Mascarenhas L; Ritchey AK; Termuhlen AM; Carroll WL; Relling MV; Wong FL; Bhatia S
J Clin Oncol; 2017 May; 35(15):1730-1736. PubMed ID: 28339328
[TBL] [Abstract][Full Text] [Related]
40. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Lange BJ; Blatt J; Sather HN; Meadows AT
Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
